首页> 美国卫生研究院文献>Diagnostics >Comparison of Commercial ELISA Kits a Prototype Multiplex Electrochemoluminescent Assay and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
【2h】

Comparison of Commercial ELISA Kits a Prototype Multiplex Electrochemoluminescent Assay and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature

机译:商业ELISA试剂盒原型多重电化学发光测定法和基于多重珠粒的免疫测定法用于检测基于尿液的膀胱癌相关诊断特征的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.
机译:在单个测定中同时准确测量多种蛋白质的能力具有显着提高由多种生物标记物组成的临床测试效率的潜力。我们调查了两个多重蛋白阵列平台的诊断准确性,该平台可检测来自80名受试者(40名患有膀胱癌)的样本中与膀胱癌相关的诊断特征。从京都大学和奈良大学收集的尿液样本与组织学确定的膀胱癌进行了比较。 10种蛋白质的浓度(A1AT;载脂蛋白E-APOE;血管生成素-ANG;碳酸酐酶9-CA9;白介素8-IL-8;基质金属蛋白酶9-MMP-9;基质金属蛋白酶10-MMP10;纤溶酶原激活物抑制剂1-根据制造商的技术规格,使用两个原型多重阵列平台和酶联免疫吸附测定(ELISA)监测PAI-1,syndecan-SDC1和血管内皮生长因子(VEGF)。尽管在商用ELISA试剂盒中定量下限(LLOQ)通常较低,但在多重检测中检测每种生物标记物的范围有所改善。据报道,基于多重珠的免疫测定(MBA)的原型多重测定的接收器工作特征(AUROC)下面积为0.97,对于多重电化学发光测定(MEA)的面积为0.86。 MBA的敏感性和特异性分别为0.93和0.95,而MEA的敏感性和特异性分别为0.85和0.80。 MBA的准确度,阳性预测值(PPV)和阴性预测值(NPV)分别为0.94、0.95和0.93,而MEA的准确性分别为0.83、0.81和0.84。基于这些令人鼓舞的初步数据,我们认为多重蛋白阵列是可行的平台,可以用作定量生物样品中多种蛋白质的高效且高度准确的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号